Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin

Neoplasia (United States)

Volumn 19, Issue 4, 2017, Pages 301-309

  Wiegering, Armin ^a,b   Matthes, Niels ^a   Mühling, Bettina ^a   Koospal, Monika ^a   Quenzer, Anne ^a   Peter, Stephanie ^b   Germer, Christoph Thomas ^a   Linnebacher, Michael ^c   Otto, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; HISTONE H2AX; MESSENGER RNA; MYC PROTEIN; OXALIPLATIN; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; UNCLASSIFIED DRUG; PLATINUM COMPLEX;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PATIENT; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; PRIORITY JOURNAL; TREATMENT RESPONSE; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85016727017     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2017.01.007     Document Type: Article

References (31)

1. [1] Siegel, R, Desantis, C, Jemal, A, Colorectal cancer statistics, 2014. CA Cancer J Clin 64:2 (2014), 104–117.
2. [2] Wiegering, A, Korb, D, Thalheimer, A, Kämmerer, U, Allmannritter, J, Matthes, N, Linnebacher, M, Schlegel, N, Klein, I, Ergün, S, et al. E7080, a multitargeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. Neoplasia 16:11 (2014), 972–981.
3. [3] Thalheimer, A, Otto, C, Bueter, M, Illert, B, Gattenlohner, S, Gasser, M, Meyer, D, Fein, M, Germer, CT, Waaga-Gasser, AM, The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer. BMC Cancer, 9(1), 2009, 29.
4. [4] Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
5. [5] Vogelstein, B, Lane, D, Levine, AJ, Surfing the p53 network. Nature 408:6810 (2000), 307–310.
6. [6] Harris, SL, Levine, AJ, The p53 pathway: positive and negative feedback loops. Oncogene 24:17 (2005), 2899–2908.
7. [7] Momand, J, Zambetti, GP, Olson, DC, George, D, Levine, AJ, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992), 1237–1245.
8. [8] Grinkevich, VV, Nikulenkov, F, Shi, Y, Enge, M, Bao, W, Maljukova, A, Gluch, A, Kel, A, Sangfelt, O, Selivanova, G, Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 15:5 (2009), 441–453.
9. [9] Issaeva, N, Bozko, P, Enge, M, Protopopova, M, Verhoef, LG, Masucci, M, Pramanik, A, Selivanova, G, Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:12 (2004), 1321–1328.
10. [10] Yu, X, Vazquez, A, Levine, AJ, Carpizo, DR, Allele-specific p53 mutant reactivation. Cancer Cell 21:5 (2012), 614–625.
11. [11] Bykov, VJ, Wiman, KG, Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett 588:16 (2014), 2622–2667.
12. [12] Longley, DB, Harkin, DP, Johnston, PG, 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:5 (2003), 330–338.
13. [13] Dasari, S, Tchounwou, PB, Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740 (2014), 364–378.
14. [14] Nieves-Neira, W, Rivera, MI, Kohlhagen, G, Hursey, ML, Pourquier, P, Sausville, EA, Pommier, Y, DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol 56:3 (1999), 478–484.
15. [15] Maletzki, C, Stier, S, Gruenert, U, Gock, M, Ostwald, C, Prall, F, Linnebacher, M, Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One, 7(12), 2012, e52485.
16. [16] Maletzki, C, Huehns, M, Knapp, P, Waukosin, N, Klar, E, Prall, F, Linnebacher, M, Functional characterization and drug response of freshly established patient-derived tumor models with CpG island methylator phenotype. PLoS One, 10(11), 2015, e0143194.
17. [17] Maletzki, C, Gock, M, Randow, M, Klar, E, Huehns, M, Prall, F, Linnebacher, M, Establishment and characterization of cell lines from chromosomal instable colorectal cancer. World J Gastroenterol 21:1 (2015), 164–176.
18. [18] Ahmed, D, Eide, PW, Eilertsen, IA, Danielsen, SA, Eknæs, M, Hektoen, M, Lind, GE, Lothe, RA, Epigenetic and genetic features of 24 colon cancer cell lines. Oncogene, 2, 2013, e71, 10.1038/oncsis.2013.35.
19. [19] Chen, TR, Dorotinsky, CS, McGuire, LJ, Macy, ML, Hay, RJ, DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin. Cancer Genet Cytogenet 81:2 (1995), 103–108.
20. [20] Klingelhoeffer, C, Kämmerer, U, Koospal, M, Mühling, B, Schneider, S, Kapp, M, Kübler, A, Germer, CT, Otto, C, Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med, 12, 2012, 61, 10.1186/1472-6882-12-61.
21. [21] Pfaffl, MW, A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 29(9), 2001, e45.
22. [22] Kämmerer, U, Gires, O, Pfetzer, N, Wiegering, A, Klement, RJ, Otto, C, TKTL1 expression in human malign and benign cell lines. BMC Cancer, 15, 2015, 2, 10.1186/1471-2407-15-2.
23. [23] Burkhart, CA, Watt, F, Murray, J, Pajic, M, Prokvolit, A, Xue, C, Flemming, C, Smith, J, Purmal, A, Isachenko, N, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 69:16 (2009), 6573–6580.
24. [24] Dang, CV, MYC on the path to cancer. Cell 149:1 (2012), 22–35.
25. [25] Roos, WP, Kaina, B, DNA damage-induced cell death by apoptosis. Trends Mol Med 12:9 (2006), 440–450.
26. [26] Freed-Pastor, WA, Prives, C, Mutant p53: one name, many proteins. Genes Dev 26:12 (2012), 1268–1286, 10.1101/gad.190678.112 [Review].
27. [27] Burmakin, M, Shi, Y, Hedström, E, Kogner, P, Selivanova, G, Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res 19:18 (2013), 5092–5103.
28. [28] Di Marzo, D, Forte, IM, Indovina, P, Di Gennaro, E, Rizzo, V, Giorgi, F, Mattioli, E, Iannuzzi, CA, Budillon, A, Giordano, A, et al. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle 13:4 (2014), 652–665.
29. [29] Wanzel, M, Vischedyk, JB, Gittler, MP, Gremke, N, Seiz, JR, Hefter, M, Noack, M, Savai, R, Mernberger, M, Charles, JP, et al. CRISPR-Cas9-based target validation for p53-reactivating model compounds. Nat Chem Biol 12:1 (2016), 22–28.
30. [30] Krajewski, M, Ozdowy, P, D'Silva, L, Rothweiler, U, Holak, TA, NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 11:11 (2005), 1135–1136.
31. [31] Podhorecka, M, Skladanowski, A, Bozko, P, H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids, 2010, 2010, 10.4061/2010/920161 [pii: 920161].